Corvus Pharmaceuticals (CRVS) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed Monte Rosa Therapeutics (GLUE) over the past year, gaining 51.5% versus a gain of 37.8%. Over five years, CRVS leads with a +110.3% price change compared with -52.0% for GLUE. Corvus Pharmaceuticals is the larger company by market cap ($875.7 million vs $867.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | GLUE |
|---|---|---|
| Share price | $10.41 | $10.17 |
| Market cap | $875.70M | $867.64M |
| 1-day change | -1.42% | +3.04% |
| YTD return | +35.19% | -35.14% |
| 1-year return | +51.53% | +37.80% |
| 5-year return | +110.30% | -52.03% |
| EPS (TTM) | $-0.62 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.95 | $25.77 |
| 52-week low | $6.39 | $7.65 |
| Distance from 52-week high | -61.37% | -60.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.35% | +175.32% |
| Average volume | 973.33K | 1.31M |
| Shares outstanding | 84.12M | 85.31M |
| Employees | 37 | 173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed GLUE by 13.7 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
CRVS vs GLUE FAQ
Which is bigger, Corvus Pharmaceuticals or Monte Rosa Therapeutics?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $875.70M compared with $867.64M for Monte Rosa Therapeutics (GLUE).
Which stock has performed better over the past year, CRVS or GLUE?
CRVS returned +51.53% over the past 12 months, compared with +37.80% for GLUE (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and Monte Rosa Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Corvus Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Monte Rosa Therapeutics.